Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability.

Lobello C, Bikos V, Janikova A, Pospisilova S.

Cancers (Basel). 2018 Mar 5;10(3). pii: E64. doi: 10.3390/cancers10030064. Review.

2.

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation.

Malcikova J, Tausch E, Rossi D, Sutton LA, Soussi T, Zenz T, Kater AP, Niemann CU, Gonzalez D, Davi F, Gonzalez Diaz M, Moreno C, Gaidano G, Stamatopoulos K, Rosenquist R, Stilgenbauer S, Ghia P, Pospisilova S; European Research Initiative on Chronic Lymphocytic Leukemia (ERIC) — TP53 network.

Leukemia. 2018 Feb 2. doi: 10.1038/s41375-017-0007-7. [Epub ahead of print] Review.

PMID:
29467486
3.

Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemia.

Janovska P, Verner J, Kohoutek J, Bryjova L, Gregorova M, Dzimkova M, Skabrahova H, Radaszkiewicz T, Ovesna P, Vondalova Blanarova O, Nemcova T, Hoferova Z, Vasickova K, Smyckova L, Egle A, Pavlova S, Poppova L, Plevova K, Pospisilova S, Bryja V.

Blood. 2018 Mar 15;131(11):1206-1218. doi: 10.1182/blood-2017-05-786947. Epub 2018 Jan 9.

PMID:
29317454
4.

No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy.

Baliakas P, Mattsson M, Hadzidimitriou A, Minga E, Agathangelidis A, Sutton LA, Scarfo L, Davis Z, Yan XJ, Plevova K, Sandberg Y, Vojdeman FJ, Tzenou T, Chu CC, Veronese S, Mansouri L, Smedby KE, Giudicelli V, Nguyen-Khac F, Panagiotidis P, Juliusson G, Anagnostopoulos A, Lefranc MP, Trentin L, Catherwood M, Montillo M, Niemann CU, Langerak AW, Pospisilova S, Stavroyianni N, Chiorazzi N, Oscier D, Jelinek DF, Shanafelt T, Darzentas N, Belessi C, Davi F, Ghia P, Rosenquist R, Stamatopoulos K.

Haematologica. 2018 Apr;103(4):e158-e161. doi: 10.3324/haematol.2017.182634. Epub 2017 Dec 21. No abstract available.

5.

Primaquine hybrids as promising antimycobacterial and antimalarial agents.

Pavić K, Perković I, Pospíšilová Š, Machado M, Fontinha D, Prudêncio M, Jampilek J, Coffey A, Endersen L, Rimac H, Zorc B.

Eur J Med Chem. 2018 Jan 1;143:769-779. doi: 10.1016/j.ejmech.2017.11.083. Epub 2017 Dec 2.

PMID:
29220797
6.

Expression of COBLL1 encoding novel ROR1 binding partner is robust predictor of survival in chronic lymphocytic leukemia.

Plešingerová H, Janovská P, Mishra A, Smyčková L, Poppová L, Libra A, Plevová K, Ovesná P, Radová L, Doubek M, Pavlová Š, Pospíšilová Š, Bryja V.

Haematologica. 2018 Feb;103(2):313-324. doi: 10.3324/haematol.2017.178699. Epub 2017 Nov 9.

7.

Transcription factor YY1 can control AID-mediated mutagenesis in mice.

Zaprazna K, Basu A, Tom N, Jha V, Hodawadekar S, Radova L, Malcikova J, Tichy B, Pospisilova S, Atchison ML.

Eur J Immunol. 2018 Feb;48(2):273-282. doi: 10.1002/eji.201747065. Epub 2017 Nov 14.

PMID:
29080214
8.

Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons.

Rodríguez-Vicente AE, Bikos V, Hernández-Sánchez M, Malcikova J, Hernández-Rivas JM, Pospisilova S.

Oncotarget. 2017 Jul 24;8(41):71234-71248. doi: 10.18632/oncotarget.19525. eCollection 2017 Sep 19. Review.

9.

GLASS: assisted and standardized assessment of gene variations from Sanger sequence trace data.

Pal K, Bystry V, Reigl T, Demko M, Krejci A, Touloumenidou T, Stalika E, Tichy B, Ghia P, Stamatopoulos K, Pospisilova S, Malcikova J, Darzentas N.

Bioinformatics. 2017 Dec 1;33(23):3802-3804. doi: 10.1093/bioinformatics/btx423.

PMID:
29036643
10.

Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project.

Rawstron AC, Kreuzer KA, Soosapilla A, Spacek M, Stehlikova O, Gambell P, McIver-Brown N, Villamor N, Psarra K, Arroz M, Milani R, de la Serna J, Cedena MT, Jaksic O, Nomdedeu J, Moreno C, Rigolin GM, Cuneo A, Johansen P, Johnsen HE, Rosenquist R, Niemann CU, Kern W, Westerman D, Trneny M, Mulligan S, Doubek M, Pospisilova S, Hillmen P, Oscier D, Hallek M, Ghia P, Montserrat E.

Cytometry B Clin Cytom. 2018 Jan;94(1):121-128. doi: 10.1002/cyto.b.21595. Epub 2018 Jan 17.

11.

Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL.

Brazdilova K, Plevova K, Skuhrova Francova H, Kockova H, Borsky M, Bikos V, Malcikova J, Oltova A, Kotaskova J, Tichy B, Brychtova Y, Mayer J, Doubek M, Pospisilova S.

Leukemia. 2018 Jan;32(1):234-236. doi: 10.1038/leu.2017.274. Epub 2017 Aug 29. No abstract available.

12.

Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia.

Vavrova E, Kantorova B, Vonkova B, Kabathova J, Skuhrova-Francova H, Diviskova E, Letocha O, Kotaskova J, Brychtova Y, Doubek M, Mayer J, Pospisilova S.

Leuk Res. 2017 Sep;60:145-150. doi: 10.1016/j.leukres.2017.08.001. Epub 2017 Aug 7.

PMID:
28837890
13.

MicroRNA and mesial temporal lobe epilepsy with hippocampal sclerosis: Whole miRNome profiling of human hippocampus.

Bencurova P, Baloun J, Musilova K, Radova L, Tichy B, Pail M, Zeman M, Brichtova E, Hermanova M, Pospisilova S, Mraz M, Brazdil M.

Epilepsia. 2017 Oct;58(10):1782-1793. doi: 10.1111/epi.13870. Epub 2017 Aug 16.

PMID:
28815576
14.

Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status.

Kubesova B, Pavlova S, Malcikova J, Kabathova J, Radova L, Tom N, Tichy B, Plevova K, Kantorova B, Fiedorova K, Slavikova M, Bystry V, Kissova J, Gisslinger B, Gisslinger H, Penka M, Mayer J, Kralovics R, Pospisilova S, Doubek M.

Leukemia. 2018 Feb;32(2):450-461. doi: 10.1038/leu.2017.230. Epub 2017 Jul 24.

15.

Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification.

Sutton LA, Hadzidimitriou A, Baliakas P, Agathangelidis A, Langerak AW, Stilgenbauer S, Pospisilova S, Davis Z, Forconi F, Davi F, Ghia P, Rosenquist R, Stamatopoulos K; European Research Initiative on CLL (ERIC).

Haematologica. 2017 Jun;102(6):968-971. doi: 10.3324/haematol.2017.165605. No abstract available.

16.

Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes.

Xochelli A, Baliakas P, Kavakiotis I, Agathangelidis A, Sutton LA, Minga E, Ntoufa S, Tausch E, Yan XJ, Shanafelt T, Plevova K, Boudjogra M, Rossi D, Davis Z, Navarro A, Sandberg Y, Vojdeman FJ, Scarfo L, Stavroyianni N, Sudarikov A, Veronese S, Tzenou T, Karan-Djurasevic T, Catherwood M, Kienle D, Chatzouli M, Facco M, Bahlo J, Pott C, Pedersen LB, Mansouri L, Smedby KE, Chu CC, Giudicelli V, Lefranc MP, Panagiotidis P, Juliusson G, Anagnostopoulos A, Vlahavas I, Antic D, Trentin L, Montillo M, Niemann C, Döhner H, Langerak AW, Pospisilova S, Hallek M, Campo E, Chiorazzi N, Maglaveras N, Oscier D, Gaidano G, Jelinek DF, Stilgenbauer S, Chouvarda I, Darzentas N, Belessi C, Davi F, Hadzidimitriou A, Rosenquist R, Ghia P, Stamatopoulos K.

Clin Cancer Res. 2017 Sep 1;23(17):5292-5301. doi: 10.1158/1078-0432.CCR-16-3100. Epub 2017 May 23.

PMID:
28536306
17.

[Use of Porous Hydrogel as a 3D Scaffold for the Growth of Leukemic B Lymphocytes].

Studená R, Horák D, Baloun J, Plichta Z, Pospíšilová Š.

Klin Onkol. 2017 Spring;30(Supplementum1):184-186. Czech.

PMID:
28471202
18.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice.

Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF Jr, Taschner PE, Hainaut P, Soussi T.

Cancer Res. 2017 Mar 15;77(6):1250-1260. doi: 10.1158/0008-5472.CAN-16-2179. Review.

19.

Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI.

Delgado J, Doubek M, Baumann T, Kotaskova J, Molica S, Mozas P, Rivas-Delgado A, Morabito F, Pospisilova S, Montserrat E.

Am J Hematol. 2017 Apr;92(4):375-380. doi: 10.1002/ajh.24660. Epub 2017 Feb 13.

20.

Restrictions in the T-cell repertoire of chronic lymphocytic leukemia: high-throughput immunoprofiling supports selection by shared antigenic elements.

Vardi A, Vlachonikola E, Karypidou M, Stalika E, Bikos V, Gemenetzi K, Maramis C, Siorenta A, Anagnostopoulos A, Pospisilova S, Maglaveras N, Chouvarda I, Stamatopoulos K, Hadzidimitriou A.

Leukemia. 2017 Jul;31(7):1555-1561. doi: 10.1038/leu.2016.362. Epub 2016 Nov 25.

PMID:
27904140
21.

EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia.

Young E, Noerenberg D, Mansouri L, Ljungström V, Frick M, Sutton LA, Blakemore SJ, Galan-Sousa J, Plevova K, Baliakas P, Rossi D, Clifford R, Roos-Weil D, Navrkalova V, Dörken B, Schmitt CA, Smedby KE, Juliusson G, Giacopelli B, Blachly JS, Belessi C, Panagiotidis P, Chiorazzi N, Davi F, Langerak AW, Oscier D, Schuh A, Gaidano G, Ghia P, Xu W, Fan L, Bernard OA, Nguyen-Khac F, Rassenti L, Li J, Kipps TJ, Stamatopoulos K, Pospisilova S, Zenz T, Oakes CC, Strefford JC, Rosenquist R, Damm F.

Leukemia. 2017 Jul;31(7):1547-1554. doi: 10.1038/leu.2016.359. Epub 2016 Nov 28.

PMID:
27890934
22.

Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia.

Melazzini F, Palombo F, Balduini A, De Rocco D, Marconi C, Noris P, Gnan C, Pippucci T, Bozzi V, Faleschini M, Barozzi S, Doubek M, Di Buduo CA, Kozubik KS, Radova L, Loffredo G, Pospisilova S, Alfano C, Seri M, Balduini CL, Pecci A, Savoia A.

Haematologica. 2016 Nov;101(11):1333-1342. Epub 2016 Jun 30.

23.

Comparison of MicroRNA Content in Plasma and Urine Indicates the Existence of a Transrenal Passage of Selected MicroRNAs.

Pazourkova E, Pospisilova S, Svobodova I, Horinek A, Brisuda A, Soukup V, Hrbacek J, Capoun O, Mares J, Hanus T, Babjuk M, Korabecna M.

Adv Exp Med Biol. 2016;924:97-100.

PMID:
27753026
24.

The Structure-Antimicrobial Activity Relationships of a Promising Class of the Compounds Containing the N-Arylpiperazine Scaffold.

Malík I, Csöllei J, Jampílek J, Stanzel L, Zadražilová I, Hošek J, Pospíšilová Š, Čížek A, Coffey A, O'Mahony J.

Molecules. 2016 Sep 26;21(10). pii: E1274.

25.

Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV.

Poppova L, Janovska P, Plevova K, Radova L, Plesingerova H, Borsky M, Kotaskova J, Kantorova B, Hlozkova M, Figulova J, Brychtova Y, Machalova M, Urik M, Doubek M, Kozubik A, Pospisilova S, Pavlova S, Bryja V.

Br J Haematol. 2016 Dec;175(5):851-859. doi: 10.1111/bjh.14312. Epub 2016 Sep 21.

PMID:
27651098
26.

Synthesis and Antimicrobial Evaluation of 1-[(2-Substituted phenyl)carbamoyl]naphthalen-2-yl Carbamates.

Gonec T, Pospisilova S, Holanova L, Stranik J, Cernikova A, Pudelkova V, Kos J, Oravec M, Kollar P, Cizek A, Jampilek J.

Molecules. 2016 Sep 7;21(9). pii: E1189. doi: 10.3390/molecules21091189.

27.

N-Alkoxyphenylhydroxynaphthalenecarboxamides and Their Antimycobacterial Activity.

Gonec T, Pospisilova S, Kauerova T, Kos J, Dohanosova J, Oravec M, Kollar P, Coffey A, Liptaj T, Cizek A, Jampilek J.

Molecules. 2016 Aug 16;21(8). pii: E1068. doi: 10.3390/molecules21081068.

28.

High-quality full-length immunoglobulin profiling with unique molecular barcoding.

Turchaninova MA, Davydov A, Britanova OV, Shugay M, Bikos V, Egorov ES, Kirgizova VI, Merzlyak EM, Staroverov DB, Bolotin DA, Mamedov IZ, Izraelson M, Logacheva MD, Kladova O, Plevova K, Pospisilova S, Chudakov DM.

Nat Protoc. 2016 Sep;11(9):1599-616. doi: 10.1038/nprot.2016.093. Epub 2016 Aug 4.

PMID:
27490633
29.

Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4/SDF-1 axis.

Pavlasova G, Borsky M, Seda V, Cerna K, Osickova J, Doubek M, Mayer J, Calogero R, Trbusek M, Pospisilova S, Davids MS, Kipps TJ, Brown JR, Mraz M.

Blood. 2016 Sep 22;128(12):1609-13. doi: 10.1182/blood-2016-04-709519. Epub 2016 Aug 1.

30.

ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres.

Navrkalova V, Young E, Baliakas P, Radova L, Sutton LA, Plevova K, Mansouri L, Ljungström V, Ntoufa S, Davis Z, Juliusson G, Smedby KE, Belessi C, Panagiotidis P, Touloumenidou T, Davi F, Langerak AW, Ghia P, Strefford JC, Oscier D, Mayer J, Stamatopoulos K, Pospisilova S, Rosenquist R, Trbusek M.

Haematologica. 2016 Sep;101(9):e369-73. doi: 10.3324/haematol.2016.142968. Epub 2016 Jun 16. No abstract available.

31.

Single cell analysis revealed a coexistence of NOTCH1 and TP53 mutations within the same cancer cells in chronic lymphocytic leukaemia patients.

Kantorova B, Malcikova J, Brazdilova K, Borsky M, Plevova K, Smardova J, Radova L, Tom N, Trbusek M, Diviskova E, Francova HS, Navrkalova V, Doubek M, Brychtova Y, Mayer J, Pospisilova S.

Br J Haematol. 2017 Sep;178(6):979-982. doi: 10.1111/bjh.14176. Epub 2016 Jul 29. No abstract available.

PMID:
27470445
32.

MicroRNAs in urine supernatant as potential non-invasive markers for bladder cancer detection.

Pospisilova S, Pazourkova E, Horinek A, Brisuda A, Svobodova I, Soukup V, Hrbacek J, Capoun O, Hanus T, Mares J, Korabecna M, Babjuk M.

Neoplasma. 2016;63(5):799-808. doi: 10.4149/neo_2016_518.

PMID:
27468885
33.

Differentially expressed miRNAs in trisomy 21 placentas.

Svobodová I, Korabečná M, Calda P, Břešťák M, Pazourková E, Pospíšilová Š, Krkavcová M, Novotná M, Hořínek A.

Prenat Diagn. 2016 Aug;36(8):775-84. doi: 10.1002/pd.4861. Epub 2016 Jul 18.

PMID:
27323694
34.

Ability to downregulate the level of cyclin-dependent kinase inhibitor p27Kip1 after DNA damage is retained in chronic lymphocytic leukemia cells with functional ATM/p53 signaling pathway.

Raskova Kafkova L, Navrkalova V, Jarosova M, Loja T, Chovancova J, Kucerova J, Kriegova E, Prochazka V, Novak Z, Simkova D, Pospisilova S, Divoky V.

Leuk Lymphoma. 2017 Jan;58(1):199-203. Epub 2016 Jun 7. No abstract available.

PMID:
27268868
35.

Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors.

Sutton LA, Young E, Baliakas P, Hadzidimitriou A, Moysiadis T, Plevova K, Rossi D, Kminkova J, Stalika E, Pedersen LB, Malcikova J, Agathangelidis A, Davis Z, Mansouri L, Scarfò L, Boudjoghra M, Navarro A, Muggen AF, Yan XJ, Nguyen-Khac F, Larrayoz M, Panagiotidis P, Chiorazzi N, Niemann CU, Belessi C, Campo E, Strefford JC, Langerak AW, Oscier D, Gaidano G, Pospisilova S, Davi F, Ghia P, Stamatopoulos K, Rosenquist R; ERIC, the European Research Initiative on CLL.

Haematologica. 2016 Aug;101(8):959-67. doi: 10.3324/haematol.2016.141812. Epub 2016 May 19.

36.

COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status.

Plesingerova H, Librova Z, Plevova K, Libra A, Tichy B, Skuhrova Francova H, Vrbacky F, Smolej L, Mayer J, Bryja V, Doubek M, Pospisilova S.

Leuk Lymphoma. 2017 Jan;58(1):70-79. Epub 2016 May 17.

PMID:
27185377
37.

Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference.

Baliakas P, Puiggros A, Xochelli A, Sutton LA, Nguyen-Khac F, Gardiner A, Plevova K, Minga E, Hadzidimitriou A, Walewska R, McCarthy H, Ortega M, Collado R, González T, Granada I, Luño E, Kotašková J, Moysiadis T, Davis Z, Stavroyianni N, Anagnostopoulos A, Strefford JC, Pospisilova S, Davi F, Athanasiadou A, Rosenquist R, Oscier D, Espinet B, Stamatopoulos K.

Haematologica. 2016 Jul;101(7):e299-302. doi: 10.3324/haematol.2015.140202. Epub 2016 Apr 21. No abstract available.

38.

Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression.

Kopparapu PK, Bhoi S, Mansouri L, Arabanian LS, Plevova K, Pospisilova S, Wasik AM, Croci GA, Sander B, Paulli M, Rosenquist R, Kanduri M.

Epigenetics. 2016 May 3;11(5):335-43. doi: 10.1080/15592294.2016.1164375. Epub 2016 Apr 6.

39.

Innovation in the prognostication of chronic lymphocytic leukemia: how far beyond TP53 gene analysis can we go?

Pospisilova S, Sutton LA, Malcikova J, Tausch E, Rossi D, Montserrat E, Moreno C, Stamatopoulos K, Gaidano G, Rosenquist R, Ghia P; European Research Initiative on CLL (ERIC).

Haematologica. 2016 Mar;101(3):263-5. doi: 10.3324/haematol.2015.139246. No abstract available.

40.

[Identification of a Family with SUFU Germline Deletion Based on a Case of Desmoplastic Medulloblastoma in an Infant].

Šoukalová J, Vejmělková K, Cermanová T, Kašíková K, Mikulášová A, Janyšková H, Melichárková K, Pavelka Z, Ježová M, Pospíšilová Š, Kuglík P, Valášková I, Gaillyová R, Štěrba J, Zitterbart K.

Klin Onkol. 2016;29 Suppl 1:S83-8. Czech.

PMID:
26691947
41.

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations.

Ljungström V, Cortese D, Young E, Pandzic T, Mansouri L, Plevova K, Ntoufa S, Baliakas P, Clifford R, Sutton LA, Blakemore SJ, Stavroyianni N, Agathangelidis A, Rossi D, Höglund M, Kotaskova J, Juliusson G, Belessi C, Chiorazzi N, Panagiotidis P, Langerak AW, Smedby KE, Oscier D, Gaidano G, Schuh A, Davi F, Pott C, Strefford JC, Trentin L, Pospisilova S, Ghia P, Stamatopoulos K, Sjöblom T, Rosenquist R.

Blood. 2016 Feb 25;127(8):1007-16. doi: 10.1182/blood-2015-10-674572. Epub 2015 Dec 16.

42.

An Immunogenetic Signature of Ongoing Antigen Interactions in Splenic Marginal Zone Lymphoma Expressing IGHV1-2*04 Receptors.

Bikos V, Karypidou M, Stalika E, Baliakas P, Xochelli A, Sutton LA, Papadopoulos G, Agathangelidis A, Papadopoulou E, Davis Z, Algara P, Kanellis G, Traverse-Glehen A, Mollejo M, Anagnostopoulos A, Ponzoni M, Gonzalez D, Pospisilova S, Matutes E, Piris MA, Papadaki T, Ghia P, Rosenquist R, Oscier D, Darzentas N, Tzovaras D, Belessi C, Hadzidimitriou A, Stamatopoulos K.

Clin Cancer Res. 2016 Apr 15;22(8):2032-40. doi: 10.1158/1078-0432.CCR-15-1170. Epub 2015 Dec 8.

43.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Rawstron AC, Fazi C, Agathangelidis A, Villamor N, Letestu R, Nomdedeu J, Palacio C, Stehlikova O, Kreuzer KA, Liptrot S, O'Brien D, de Tute RM, Marinov I, Hauwel M, Spacek M, Dobber J, Kater AP, Gambell P, Soosapilla A, Lozanski G, Brachtl G, Lin K, Boysen J, Hanson C, Jorgensen JL, Stetler-Stevenson M, Yuan C, Broome HE, Rassenti L, Craig F, Delgado J, Moreno C, Bosch F, Egle A, Doubek M, Pospisilova S, Mulligan S, Westerman D, Sanders CM, Emerson R, Robins HS, Kirsch I, Shanafelt T, Pettitt A, Kipps TJ, Wierda WG, Cymbalista F, Hallek M, Hillmen P, Montserrat E, Ghia P.

Leukemia. 2016 Apr;30(4):929-36. doi: 10.1038/leu.2015.313. Epub 2015 Dec 7.

44.

ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells.

Kotašková J, Pavlová Š, Greif I, Stehlíková O, Plevová K, Janovská P, Brychtová Y, Doubek M, Pospíšilová Š, Bryja V.

Br J Haematol. 2016 Oct;175(2):339-342. doi: 10.1111/bjh.13848. Epub 2015 Nov 16. No abstract available.

PMID:
26567475
45.

[Molecular Prognostic Markers and Their Clinical Relevance in Chronic Lymphocytic Leukemia].

Navrkalová V, Kantorová B, Jarošová M, Pospíšilová Š.

Klin Onkol. 2015;28 Suppl 3:3S6-15. Review. Czech.

PMID:
26489496
46.

Histone H1 Differentially Inhibits DNA Bending by Reduced and Oxidized HMGB1 Protein.

Štros M, Polanská E, Kučírek M, Pospíšilová Š.

PLoS One. 2015 Sep 25;10(9):e0138774. doi: 10.1371/journal.pone.0138774. eCollection 2015.

47.

The impact of standard chemotherapy on miRNA signature in plasma in AML patients.

Koutova L, Sterbova M, Pazourkova E, Pospisilova S, Svobodova I, Horinek A, Lysak D, Korabecna M.

Leuk Res. 2015 Dec;39(12):1389-95. doi: 10.1016/j.leukres.2015.08.009. Epub 2015 Aug 20.

PMID:
26340914
48.

Urinary Cell-Free DNA Quantification as Non-Invasive Biomarker in Patients with Bladder Cancer.

Brisuda A, Pazourkova E, Soukup V, Horinek A, Hrbáček J, Capoun O, Svobodova I, Pospisilova S, Korabecna M, Mares J, Hanuš T, Babjuk M.

Urol Int. 2016;96(1):25-31. doi: 10.1159/000438828. Epub 2015 Sep 3.

PMID:
26338254
49.

Oxidative stress as a therapeutic perspective for ATM-deficient chronic lymphocytic leukemia patients.

Navrkalova V, Kafkova LR, Divoky V, Pospisilova S.

Haematologica. 2015 Aug;100(8):994-6. doi: 10.3324/haematol.2015.130260. No abstract available.

50.

Prognostic relevance of MYD88 mutations in CLL: the jury is still out.

Baliakas P, Hadzidimitriou A, Agathangelidis A, Rossi D, Sutton LA, Kminkova J, Scarfo L, Pospisilova S, Gaidano G, Stamatopoulos K, Ghia P, Rosenquist R.

Blood. 2015 Aug 20;126(8):1043-4. doi: 10.1182/blood-2015-05-648634. No abstract available.

Supplemental Content

Loading ...
Support Center